ZA200701868B - Ileitis diagnostic assay - Google Patents

Ileitis diagnostic assay Download PDF

Info

Publication number: ZA200701868B
Authority: ZA; South Africa
Prior art keywords: antigen; immunoassay; animal; antibodies; lipopolysaccharide
Prior art date: 2004-08-13

Application number

ZA200701868A

Other languages

English (en)

Inventor

Jeremy J Kroll

Michael B Roof

Marc A Eichmeyer

Original Assignee

Boehringer Ingelheim Vetmed

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-13

Filing date

2005-08-10

Publication date

2008-07-30

2005-08-10 Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed

2008-07-30 Publication of ZA200701868B publication Critical patent/ZA200701868B/en

Links

238000003556 assay Methods 0.000 title description 20
208000009326 ileitis Diseases 0.000 title description 4
239000000427 antigen Substances 0.000 claims description 57
239000002158 endotoxin Substances 0.000 claims description 56
102000036639 antigens Human genes 0.000 claims description 55
108091007433 antigens Proteins 0.000 claims description 55
241001148567 Lawsonia intracellularis Species 0.000 claims description 50
229920006008 lipopolysaccharide Polymers 0.000 claims description 49
238000012360 testing method Methods 0.000 claims description 35
238000003018 immunoassay Methods 0.000 claims description 33
241000282887 Suidae Species 0.000 claims description 23
241001465754 Metazoa Species 0.000 claims description 20
238000002965 ELISA Methods 0.000 claims description 16
230000007689 endotoxicity Effects 0.000 claims description 7
230000001747 exhibiting effect Effects 0.000 claims description 5
230000028993 immune response Effects 0.000 claims description 4
241000282472 Canis lupus familiaris Species 0.000 claims description 3
241000700198 Cavia Species 0.000 claims description 3
241000282994 Cervidae Species 0.000 claims description 3
241000699800 Cricetinae Species 0.000 claims description 3
241000271559 Dromaiidae Species 0.000 claims description 3
241000283086 Equidae Species 0.000 claims description 3
241000282560 Macaca mulatta Species 0.000 claims description 3
241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
241000700159 Rattus Species 0.000 claims description 3
241000271567 Struthioniformes Species 0.000 claims description 3
241000596212 Vulpes lagopus Species 0.000 claims description 3
210000003022 colostrum Anatomy 0.000 claims description 3
235000021277 colostrum Nutrition 0.000 claims description 3
210000003608 fece Anatomy 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
210000003296 saliva Anatomy 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims 3
230000003100 immobilizing effect Effects 0.000 claims 2
210000002966 serum Anatomy 0.000 description 20
238000010790 dilution Methods 0.000 description 17
239000012895 dilution Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
238000001514 detection method Methods 0.000 description 15
238000000034 method Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
241000282898 Sus scrofa Species 0.000 description 12
230000000903 blocking effect Effects 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000872 buffer Substances 0.000 description 9
229940027941 immunoglobulin g Drugs 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000011534 incubation Methods 0.000 description 8
239000013641 positive control Substances 0.000 description 8
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000000758 substrate Substances 0.000 description 7
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
230000003902 lesion Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
102000003992 Peroxidases Human genes 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
108040007629 peroxidase activity proteins Proteins 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241001469654 Lawsonia <weevil> Species 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
150000004676 glycans Polymers 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
235000013861 fat-free Nutrition 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000008719 thickening Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
229920002799 BoPET Polymers 0.000 description 2
241000283707 Capra Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
-1 KDO Chemical class 0.000 description 2
239000005041 Mylar™ Substances 0.000 description 2
229920002274 Nalgene Polymers 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012470 diluted sample Substances 0.000 description 2
231100000676 disease causative agent Toxicity 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
208000037902 enteropathy Diseases 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000028774 intestinal disease Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
235000020030 perry Nutrition 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012089 stop solution Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
241000277275 Oncorhynchus mykiss Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
244000088415 Raphanus sativus Species 0.000 description 1
235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
206010047897 Weight gain poor Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000001446 dark-field microscopy Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000013578 denaturing buffer Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011847 diagnostic investigation Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
239000003517 fume Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000012474 protein marker Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
JWUKKEHXERVSKS-UHFFFAOYSA-M silver;periodate Chemical compound [Ag+].[O-]I(=O)(=O)=O JWUKKEHXERVSKS-UHFFFAOYSA-M 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G99/00—Subject matter not provided for in other groups of this subclass
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

ZA200701868A 2004-08-13 2005-08-10 Ileitis diagnostic assay ZA200701868B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/918,006 US7550270B2 (en)	2004-08-13	2004-08-13	Ileitis diagnostic assay

Publications (1)

Publication Number	Publication Date
ZA200701868B true ZA200701868B (en)	2008-07-30

Family

ID=35800427

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200701868A ZA200701868B (en)	2004-08-13	2005-08-10	Ileitis diagnostic assay

Country Status (17)

Country	Link
US (1)	US7550270B2 (de)
EP (1)	EP1789800B1 (de)
JP (1)	JP2008510145A (de)
KR (1)	KR20070049643A (de)
CN (1)	CN101065666A (de)
AR (1)	AR050213A1 (de)
AT (1)	ATE431930T1 (de)
AU (1)	AU2005272872A1 (de)
BR (1)	BRPI0514337A (de)
CA (1)	CA2576867A1 (de)
DE (1)	DE602005014560D1 (de)
DK (1)	DK1789800T3 (de)
MX (1)	MX2007001758A (de)
RU (1)	RU2007109151A (de)
TW (1)	TW200622247A (de)
WO (1)	WO2006020730A2 (de)
ZA (1)	ZA200701868B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) *	2005-07-15	2013-03-19	Boehringer Ingelheim Vetmedica, Inc.	Lawsonia vaccine and methods of use thereof
US8470336B2 (en) *	2006-05-25	2013-06-25	Boehringer Ingelheim Vetmedica, Inc.	Vaccination of young animals against Lawsonia intracellularis infections
US20080241190A1 (en) *	2006-11-13	2008-10-02	Boehringer Ingelheim Vetmedica, Inc.	Vaccination of horses against lawsonia intracellularis
WO2008073464A2 (en)	2006-12-11	2008-06-19	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
US8398970B2 (en) *	2007-09-17	2013-03-19	Boehringer Ingelheim Vetmedica, Inc.	Method of preventing early Lawsonia intracellularis infections
JP5723772B2 (ja) *	2008-07-22	2015-05-27	インターベットインターナショナルベー．フェー．	新規血清型のローソニア・イントラセルラリス細菌、その細菌に基づくワクチン、該新規ローソニア・イントラセルラリス血清型の特定に適した抗体および該抗体を製造するためのハイブリドーマ
JP2017512477A (ja) *	2014-03-28	2017-05-25	コンジュゴン，インコーポレーテッド	治療細菌の小型コロニー変種の調製
CN105699640B (zh) *	2014-05-07	2017-06-06	北京中生金域诊断技术股份有限公司	一种检测肠道屏障功能的试剂盒
MX2020008913A (es) *	2018-02-28	2020-10-01	Boehringer Ingelheim Vetmedica Gmbh	Metodo para reducir el escatol y/o indol en animales.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI224107B (en) *	1998-10-22	2004-11-21	Pfizer Prod Inc	Novel proteins from actinobacillus pleuropneumoniae
WO2002026250A2 (en) *	2000-09-29	2002-04-04	Arizona Board Of Regents On Behalf Of The University Of Arizona	Vaccines for proliferative ileitis

2004
- 2004-08-13 US US10/918,006 patent/US7550270B2/en not_active Expired - Lifetime
2005
- 2005-08-10 BR BRPI0514337-3A patent/BRPI0514337A/pt not_active IP Right Cessation
- 2005-08-10 KR KR1020077003770A patent/KR20070049643A/ko not_active Withdrawn
- 2005-08-10 DE DE602005014560T patent/DE602005014560D1/de not_active Expired - Lifetime
- 2005-08-10 RU RU2007109151/15A patent/RU2007109151A/ru not_active Application Discontinuation
- 2005-08-10 AT AT05785315T patent/ATE431930T1/de not_active IP Right Cessation
- 2005-08-10 EP EP05785315A patent/EP1789800B1/de not_active Expired - Lifetime
- 2005-08-10 MX MX2007001758A patent/MX2007001758A/es not_active Application Discontinuation
- 2005-08-10 CN CNA2005800323134A patent/CN101065666A/zh active Pending
- 2005-08-10 JP JP2007525772A patent/JP2008510145A/ja active Pending
- 2005-08-10 AU AU2005272872A patent/AU2005272872A1/en not_active Abandoned
- 2005-08-10 DK DK05785315T patent/DK1789800T3/da active
- 2005-08-10 WO PCT/US2005/028464 patent/WO2006020730A2/en not_active Ceased
- 2005-08-10 CA CA002576867A patent/CA2576867A1/en not_active Abandoned
- 2005-08-10 ZA ZA200701868A patent/ZA200701868B/en unknown
- 2005-08-12 AR ARP050103419A patent/AR050213A1/es not_active Application Discontinuation
- 2005-08-15 TW TW094127712A patent/TW200622247A/zh unknown

Also Published As

Publication number	Publication date
EP1789800B1 (de)	2009-05-20
TW200622247A (en)	2006-07-01
US20060035287A1 (en)	2006-02-16
CA2576867A1 (en)	2006-02-23
EP1789800A2 (de)	2007-05-30
AU2005272872A1 (en)	2006-02-23
DE602005014560D1 (de)	2009-07-02
US7550270B2 (en)	2009-06-23
ATE431930T1 (de)	2009-06-15
AR050213A1 (es)	2006-10-04
RU2007109151A (ru)	2008-09-20
WO2006020730A3 (en)	2006-07-27
WO2006020730A2 (en)	2006-02-23
BRPI0514337A (pt)	2008-06-10
EP1789800A4 (de)	2007-10-03
KR20070049643A (ko)	2007-05-11
CN101065666A (zh)	2007-10-31
MX2007001758A (es)	2007-04-23
DK1789800T3 (da)	2009-09-07
JP2008510145A (ja)	2008-04-03

Publication	Publication Date	Title
Díaz-Aparicio et al.	1994	Evaluation of serological tests for diagnosis of Brucella melitensis infection of goats
Guezala et al.	2009	Development of a species-specific coproantigen ELISA for human Taenia solium taeniasis
KR101621038B1 (ko)	2016-05-16	에를리히아 카니스 ｄｉｖａ（감염된 동물을 백신접종된 동물과 구별）
CN101144818B (zh)	2011-04-27	检测猪瘟病毒特异性抗体的方法及其酶联免疫试剂盒
EP1789800B1 (de)	2009-05-20	Ileitis-diagnosetest
Kroll et al.	2005	Lipopolysaccharide-based enzyme-linked immunosorbent assay for experimental use in detection of antibodies to Lawsonia intracellularis in pigs
DK2609428T3 (en)	2016-05-17	STRENGTH TEST FOR VACCINE FORMULATIONS
Wang et al.	2015	Development of an improved competitive ELISA based on a monoclonal antibody against lipopolysaccharide for the detection of bovine brucellosis
McNulty et al.	1984	Applications of immunofluorescence in veterinary viral diagnosis
Hartman et al.	1984	Serodiagnosis of canine leptospirosis by solid-phase enzyme-linked immunosorbent assay
Trueba et al.	1990	Evaluation of an enzyme immunoassay for diagnosis of bovine leptospirosis caused by Leptospira interrogans serovar hardjo type hardjo-bovis
PT2748612T (pt)	2017-11-21	Diagnósticos de vacina melhorados
Kunz et al.	1991	Immunohistochemical detection of chlamydiae in formalin‐fixed tissue sections: comparison of a monoclonal antibody with yolk derived antibodies (IgY)
de Hormaeche et al.	1986	Definition of a virulence-related antigen of Neisseria gonorrhoeae with monoclonal antibodies and lectins
Dzbeński et al.	1994	Detection of a circulating parasitic antigen in acute infections with Trichinella spiralis: diagnostic significance of findings
Sullivan et al.	1994	Monoclonal antibody to native P39 protein from Borrelia burgdorferi
MATSUNO et al.	1991	Antigenic analysis of feline and bovine Chlamydia psittaci with monoclonal antibodies
Eid et al.	2021	Comparative ELISA and SAT assays for the detection of Ornithobacterium rhinotracheale antibodies in broiler chickens at Sharkia Governorate
Ekwall et al.	1984	Specific identification of Salmonella serogroup E antigen O3 by immunofluorescence and coagglutination with antiserum elicited by a synthetic trisaccharide-bovine serum albumin glycoconjugate
US10175236B2 (en)	2019-01-08	Use of Leptospira fainei serovar hurstbridge bacteria for diagnosing leptospirosis
RU2726484C1 (ru)	2020-07-14	Способ диагностики риккетсиозов группы клещевой пятнистой лихорадки, иммуноферментная диагностическая тест-система для его осуществления
Li et al.	1992	A rapid method for detection of Yersinia enterocolitica serotype O: 3 in pig feces using monoclonal antibodies
SURUJBALLI	1997	AN INDIRECT ENZYME‐LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF LEPTOSPIRA INTERROGANS SEROVAR POMONA ANTIBODIES IN BOVINE SERA
WO2023250481A2 (en)	2023-12-28	Rickettsia igm assay
AU2005279070A1 (en)	2006-03-09	Method and kit for determining the immunisation status of a person